Myocardial perfusion imaging method
AssigneeGilead Palo Alto, Inc.
InventorLuiz Belardinelli
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for myocardial imaging by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof A2A adenosine receptor agonist to a human undergoing myocardial imaging. The invention also relates to methods of producing coronary vasodilation without significant peripheral vasodilation by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof adenosine A2A adenosine receptor agonist to a human.
Claims26
A method of producing coronary vasodilation without significant peripheral vasodilation comprising administering by intravenous (iv) bolus at least 10 μg of the A2A receptor agonist CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula:
- to a human in need thereof.
A method of myocardial perfusion imaging of a human, comprising administering a radionuclide and the A2A receptor agonist CVT-3146, named (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula:
- to the human, wherein the administration of the A2A receptor agonist causes at least a 2.5 fold increase in coronary blood flow that is achieved within about 1 minute from the administration of the A2A receptor agonist, and wherein the myocardium is examined for areas of insufficient blood flow following administration of the radionuclide and the A2A receptor agonist.
Dependencies are inferred from the claim text.